Document:

SEC Connect

***Text
Omitted and Filed Separately

with
the Securities and Exchange Commission.

Confidential
Treatment Requested

Under
17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 of the

Securities
Act of 1934, as amended.

Exhibit 10.1

Addendum
to

Nicotinamide
Riboside Supply Agreement between

Thorne
Research, Inc. & Chromadex, Inc.

Nicotinamide Riboside-Choline and/or Betaine

and/or Dimethylglycine Combination Product

	

Seller

	

Chromadex,
Inc.

	

Buyer

	

Thorne
Research, Inc.

	

Product

	

Nicotinamide
Riboside Chloride (Product Specification attached
hereto)

	

Term

	

As
defined by the NIAGEN® SUPPLY AGREEMENT, dated July 9, 2013
(“Original Agreement”)

	

Intent

	

1) To add Choline and/or
Betaine and/or dimethylglycine (DMG) to the Original
Agreement (hereinafter the NR-Choline-Betaine-DMG Combination
Product)

2) To permit Buyer the
sole rights to the Combination of Nicotinamide Riboside (NR) with
Choline and/or Betaine and/or DMG (all
forms)

3) To permit Buyer the
right to engage in the research, advertising, promotion,
manufacturing, packaging, shipment, distribution, use, offer for
sale, and sale of the NR-Choline-Betaine-DMG Combination
Product or of Derivatives of the NR-Choline-Betaine-DMG Combination
Product

4) Derivatives of the
NR-Choline-Betaine-DMG
Combination

	
 

	

Product
are defined as any product that contains the NR-Choline-Betaine-DMG Combination in
combination with any other ingredient(s)

 

 

-1-

 

 

 

	

Exclusivity
in the Territory

	

1) Thorne
retains exclusivity for stand-alone NR in the Licensed Health Care Professionals
Channel in North America.

2) Thorne
obtains Exclusive Supply of NR-Choline-Betaine-DMG
Combination

3) Thorne
retains Non-exclusive right for NR combined with any form of
folate or B12.

	

Exclusivity
Requirements

	

Exclusivity in the
Territory will be maintained if between the Effective Date of the
First Amendment and September 9, 2015, the Buyer purchases a
minimum [...***...] dollars
($[...***...]) of Product ([...***...]kg at
$[...***...]/kg) and a minimum of [...***...]
dollars ($[...***...]) of the Product at a price of
$[...***...]kg in the third year of the contract with Year
3 to begin on October 1, 2015. Buyer shall place binding quarterly
POs in Year 3 for at least $[...***...] of Product to
maintain exclusivity.”

1) Product Launch
Requirements: Thorne Research has 1 year to launch the NR-Choline-Betaine Combination Product
and 11⁄2 years to
launch  Choline and/or
Betaine and/or
dimethylglycine (DMG)

2)  Clinical Study
Requirements: Thorne will start a human clinical study within 6
months of signing this Term Sheet.

Ownership of all
Property will be transferred to ChromaDex if above requirements are
not met. On a confidential basis, ChromaDex shall access to all
data and reports generated from the Clinical Study.

	

Technology

	

Formulations of the
NR-Choline-Betaine-DMG
Combination Product or of Derivatives of the NR-Choline-Betaine-DMG Combination
Product.

Form of
Choline to include all present and future forms of choline, which
presently includes, but is not limited to:

Choline
citrate (Citicholine)

Choline
bitartrate

Phosphatidylcholine

 

*** Confidential Treatment
Requested

 

-2-

 

 

	
 

	

alpha-GPC (L-Alpha
Glycerylphosphorylcholine)

CDP
Choline (cytidine 5′-diphosphocholine)

Form of
Betaine to include all present and future forms of betaine, which
presently includes, but is not limited to:

Betaine
monohydrate

Betaine
anhydrous

Trimethylglycine
(TMG)

Forms
of Dimethylglycine (DMG) to include all present and future forms of
DMG

	

Territory

	

1) Retain
Licensed Health Care
Professionals channel in North America for stand-alone
NR

2) North
America for NR-Choline-Betaine-DMG
Combination with a right of first refusal for other
countries.

	

Field
of Use

	

Human

 

  

 

-3-

 

 

	

Channel
of Distribution

(“Channel”)

	

1) Thorne
retains the exclusive right to engage in the research, advertising,
promotion, manufacturing, packaging, shipment, distribution, use,
offer for sale, and sale of the Nicotinamide Riboside Product or of
Derivatives of the Nicotinamide
Riboside Product in the Channel defined as Licensed Health Care Professionals

 

2) This
addendum governs Thorne’s right to engage in the research,
advertising, promotion, manufacturing, packaging, shipment,
distribution, use, offer for sale, and sale of the NR-Choline-Betaine-DMG Combination or of
Derivatives of the NR-Choline-Betaine-DMG Combination
across all Channels in the Territory , with the exception of
channels in which ChromaDex has already granted or grants
exclusivity to third parties as set forth below. In those channels,
Thorne is prohibited from selling any product containing NR
(NIAGEN®).

 

3) ChromaDex
is currently selling the Product to customers that market and sell
multi-vitamins containing the Product and will continue to pursue
relationships with such parties. These multi-vitamins contain a
multitude of ingredients, including Choline, Betaine, and DMG.
However, in all channels, other ChromaDex NR Buyers would be excluded from
marketing the NR-Choline-Betaine-DMG Combination,
according to the following guidelines: 

 

Amounts of Choline, TMG, or DMG in
Relation to the Nicotinamide Riboside Content Permitted in Products
Marketed & Sold by Non-Thorne Vendors§

 

 

*Refers
to the Total Daily Dose of methyl donors in aggregate. Individual
amounts of choline, TMG, or DMG to be added are at the
vendor’s discretion, with the total of any combination
thereof to not exceed the amount listed in the table.Thorne shall
not unreasonably deny ChromaDex’s reasonable request for an
exception to the above guidelines.

 

4) ChromaDex
NR Buyers would also be excluded from marketing, offering for sale,
or selling the NR-Choline-Betaine-DMG Combination with
“methyl donor” claims, with the methylation message, or
by describing such relationship between NR, choline, betaine,
and/or NR. Further, ChromaDex NR Buyers would be excluded from
marketing, offering for sale, or selling NR-Choline-Betaine-DMG Combination with
reference to any published clinical studies using the NR-Choline-Betaine-DMG Combination. Both
Parties agree to monitor violations of this clause and ChromaDex
will use best efforts to enforce any violations of this
clause.

 

5) Any
subsidiary rights to use the NR-Choline-Betaine-DMG Combination would
have to be obtained through Thorne Research, Inc. and would be done
so at the sole discretion of Thorne Research, Inc.

 

  

 

-4-

 

 

 

	

Current
Exclusions to Sale of Product

	

1) Excluded
products include energy shots or melts (melting or dissolvable
tablet or delivery system)

2) Excluded
Fields/Channels: The “Multi-Level Marketing Channel”
defined as the sale of products through a network of independent
marketing representatives and the “Direct Response
Channel” defined as the marketing and advertising of the
Product through direct response television and radio advertisements
of any length or format intended to reach one or more potential
consumers asking them to purchase from or respond directly to Buyer
or its agent via a website, telephone number, or other medium to
purchase.

3) Channels/Fields/Products
may be excluded at any time at the sole discretion of Seller upon
written notice, unless the Parties have previously agreed in
writing that such channel/field/product may not be excluded because
Buyer has demonstrated established sales of or other commitment to
a specified channel/field/product.

	

What is
Covered by the Addendum

	

Commensurate with
the Original Agreement

	

Property

	

Trademarks,
patents, data, trade secrets, science, technology, formulas,
know-how, intellectual property, clinical research data (including
data generated by Thorne), or other information relating to any
NR-Choline-Betaine-DMG
Combination Product

	

Registration

	

The
parties will determine responsibilities for registration in the
appropriate jurisdictions

	

Regulatory
Category

	

1) Dietary
supplements

2) Thorne
Research also obtains the right to co-market the NR-Choline-Betaine-DMG Combination with
specific drugs (drugs, OTC drugs, or botanical drugs) approved for
specific diseases or conditions

3) Thorne
Research further expresses its interest to pursue the right to
develop the NR-Choline-Betaine-DMG
Combination AS a drug approved for specific diseases or
conditions. This can be governed by a first right of refusal in the
Original Agreement or governed by a separate agreement addressing
the NR-Choline prodrug
conjugate.

	

Payment
Terms

	

To be
determined

 

 

 

-5-

 

 

	

Royalties

	

Same as
original agreement

	

Research
Costs

	

NA

	

Marketing
Support

	

Method
of marketing and marketing partners to be determined by the
parties

	

Regulatory

	

As
appropriate in all Territories, Fields of Use, &
Channels

	

Assignment

	

1) No
right to assign this Agreement, except as part of transfer of
a business unit or transfer of all the activities of one of the
Parties.

	

Trademark
-

Supplier

	

Nicotinamide
Riboside has been registered by the Supplier under the NIAGEN®
trademark. Trademarks on goods developed by Supplier will be
developed, filed, owned, and maintained by Supplier.

 

	

Trademark
–

Buyer

	

Thorne
Research shall own the trademark/registration for the NR-Choline-Betaine-DMG Combination,
regardless of whether that occurs as a single product or the
NR-Choline-Betaine-DMG
Combination occurs as an ingredient in one or more finished
products. Trademarks on finished goods developed by Buyer will be
developed, filed, owned, and maintained by Buyer.

	

Patent
Costs

	

Each
Party shall bear its own patent filing and maintenance costs,
unless otherwise defined in writing by this or another
Agreement

	

Patent
Filing

	

Where
relevant to new innovation

	

Patent
Defense Costs

	

To be
commensurate with the Original Agreement:

1)
Supplier shall have the obligation and first right to defend patent
infringement claims against Nicotinamide Riboside

2)
Should Supplier default, see terms of Original
Agreement

	

Milestones

	

as
described in the table below.

 

CHROMADEX,
INC.                      
THORNE
RESEARCH, Inc.

/s/ Frank
Jaksch                                
/s/ Paul
Jacobson                                           

Name: Frank
Jaksch                         
Name: Paul Jacobson

Title:  
CEO                                      
Title: CEO

Date:  
July 24,
2015                        
Date: July 24, 2015
                               

 

 

 

-6-

 

Discovery
Timeline for NR-Choline-Betaine-DMG

	

Milestone

	

1

	

2

	

3

	

4

	

Human

Clinical

	
 

	

 KGK 24 hour
Pharmacokinetics Trial at 100, 300, and 1000 mg

	

U
Copenhagen 24 hour Pharmacokinetics Trial at X mg

	

 KGK Two Month
NAD Molecular Network Trial

	

Safety/

Toxicology

	
 

	

Yes;
serum chemistry; blood cell response

	

Yes;
serum chemistry; blood cell response

	

Yes;
serum chemistry; blood cell response

	

Pharmacokinetics

	
 

	

NAD

Methylnicotinamide

Betaine

Choline

Homocysteine

Nuclear
uracil

NAD
metabolic network

 

	

NAD

Methylnicotinamide

Betaine

Choline

Homocysteine

Nuclear
uracil

NAD
metabolic network

 

	

NAD

Methylnicotinamide

Betaine

Choline

Homocysteine

Nuclear
uracil

NAD
metabolic network

 

	

Legal

	

Oringinal
Agreement Governing NR+Choline and/or Betaine and/or
DMG

	

Evaluate M2
results

	

Evaluate M3
results

Report
& acceptance of M2 results

	

 Evaluate M4
results

Report
& final acceptance of M2-4 results

	

Strategic

	

Exclusivity
around the key methyl donors choline and betaine

	

Begin
dose determination for choline, betaine, or DMG

	

Continue dose
determination for choline, betaine, or DMG

	

Final
determination of Begin dose determination for choline, betaine, or
DMG

	

Completion

	

7.10.15

 

	

Complete

	

9.20.15

	

11.20.15

	

Study
Cost

	
 

	

 TBD

	

TBD

	

TBD

	

Milestone

Cost

	

$0k

	
 

	
 

	
 

Schedule of Milestones and Costs

  

 

-7-SEC Connect

***Text
Omitted and Filed Separately

with
the Securities and Exchange Commission.

Confidential
Treatment Requested

Under
17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 of the

Securities
Act of 1934, as amended.

 

 Exhibit
10.2

 

Second
Addendum to

Nicotinamide
Riboside Supply Agreement between

Thorne
Research, Inc. & ChromaDex, Inc.

Nicotinamide Riboside-Choline and/or Betaine

and/or Dimethylglycine Combination Product

	

Seller

	

ChromaDex,
Inc.

	

Buyer

	

Thorne
Research, Inc.

	

Effective
Date

	

September 14,
2016

	

Intent
of Second Addendum

	

1) To extend the Term of the
NIAGEN® SUPPLY AGREEMENT, dated July 9, 2013 (“Original
Agreement”) between the parties.

 

2) To amend in the entirety,
the Territory, the Exclusivity in the Territory, and the
Exclusivity Requirements in the Original Agreement and in the
Addendum to the Nicotinamide Riboside Supply Agreement, dated July
24, 2015 (“Addendum”).

 

	

Term

	

October
1, 2016 through December 31, 2018

	

Territory
and Exclusivity in the Territory (amended)

	

1) Thorne
retains exclusivity for stand-alone NR in the Licensed Health Care
Professionals Channel in the United States only.

2) Thorne
retains exclusive rights to the combination of Nicotinamide
Riboside (NR) with Choline and/or Betaine and/or DMG (all forms)
(“Combination Product”) in all channels, in the United
States and Canada, with right of first refusal for other
countries.

3) Thorne
obtains exclusive rights to the combination of Nicotinamide
Riboside (NR) and Exogenous Ketones, specifically the ketone ester
3-hydroxybutyl-3-hydroxybutyrate (“Combination
Product”) and derivatives thereof in all channels, in the
United States and Canada, with right of first refusal for other countries. For the purpose of this
license, “Exogenous Ketones” refers to
b-hydroxybutyrate (or derivatives thereof), which is (are)
converted to acetoacetate via b-hydroxybutyrate dehydrogenase,
with subsequent conversion to acetoacetyl CoA, and acetyl CoA for
the purpose of entering the tricarboxylic acid cycle (TCA) and
generating cellular energy (ATP) in humans or animals. This
Ketone Combination Product is also subject to the Channel of
Distribution, as defined in the Addendum, specifically paragraph 3
and the multi-vitamins exception.

 

   

  

 

-1-

 

 

	
 

	

 

4) The
exclusivity rights set forth in this section terminate upon the
termination of Thorne’s 3-hydroxybutyl-3-hydroxybutyrate
license with Ops Fuel.

5) Thorne’s
exclusive right to the combination of Nicotinamide Riboside (NR)
with Choline and/or Betaine and/or DMG (all forms), as well as its
right to Nicotinamide Riboside (NR) and Exogenous Ketones, shall extend to Amazon
international (Amazon.com Inc (AMZN.O) 

6) For
avoidance of doubt, ChromaDex may sell into channels and/or
territories that could directly or indirectly compete with Thorne,
with product formulations that are outside those specified in this
Addendum.

7) ChromaDex
will not engage in negotiation with [...***...]in
[...***...], and will do its best to ensure no other
ChromaDex customer engages with [...***...], through the
end of [...***...].

8)  ChromaDex
will not engage in negotiation with [...***...] for
[...***...], and will do its best to ensure no other
ChromaDex customers engage with [...***...], through the
end of [...***...].

9) ChromaDex
will not engage in negotiation with [...***...] or
[...***...], and will not knowingly allow its customers to
engage with [...***...].   Thorne understands
that ChromaDex does not have control over its customers, but that
ChromaDex will use reasonable efforts to prevent its customers from
engaging in negotiations with the [...***...].

10) Other
Channels/Fields/Products may be excluded at any time at the sole
discretion of Seller upon written notice, unless the Parties have
previously agreed in writing that such channel/field/product may
not be excluded because Buyer has demonstrated established sales of
or other commitment to a specified
channel/field/product.

 

   

*** Confidential Treatment
Requested

 

 

-2-

 

 

	

Exclusivity
Requirements (amended)

	

Exclusivity in the
Territory will be maintained if Buyer meets all the following
Exclusivity Requirements:

 

1) Product Launch
Requirements: Buyer shall launch a Combination Product by end of Q1
2017 to maintain exclusivity in the United States and
Canada

 

2)  Clinical Study
Requirements: Buyer shall complete at least one human clinical
study with stand-alone NR or with a Combination Product by June 1,
2017

 

Ownership of all
intellectual property related to NR, excluding intellectual
property surrounding the NR-Ketone combination, will be transferred
to ChromaDex if above requirements are not met. On a confidential
basis, ChromaDex shall have access to all data and reports
generated from the Clinical Study.

 

3) Minimum Purchase
Requirements:

 

Q4 2016
= [...***...]kg of
NIAGEN

Q1 2017
= [...***...]kg NIAGEN*

Q2 2017
= [...***...]kg NIAGEN

Q3 2017
= [...***...]kg NIAGEN

Q4 2017
= [...***...]kg NIAGEN

Q1 2018
= [...***...]kg NIAGEN

Q2 2018
= [...***...]kg NIAGEN

Q3 2018
= [...***...]kg NIAGEN

Q4 2018
= [...***...]kg NIAGEN

* Q1 of
FY2017 will be reduced to [...***...]kg, which is a
$[...***...] savings in working capital, for the change of
the Territory for exclusivity rights for stand-alone NR from North
America to the United States in the Second Addendum.

 

For
each quarter, a binding purchase order with volume and ship date
will be provided by Buyer to Seller no less than 45 days prior to
the start of the next calendar quarter.

 

Seller
may terminate Exclusivity Rights, with written notice, if Seller
fails to meet the Exclusivity Requirements. Buyer shall have 30
days from written notice to cure.

 

	

Buyer
Obligations

	

1)        
A minimum dose in single
entity form, of 100mg will be used in Buyer’s NR product(s)
(as expressed as “per serving” on label), to insure
alignment with human study data that is published before or during
the Term.

2)        Patent
Marking. Buyer will ensure proper patent marking on all finished
product. All finished product shall be marked as follows:
“Patent: See www.ChromaDexPatents.com”.

 

 

*** Confidential Treatment
Requested

 

 

-3-

 

 

The
terms and conditions of all other sections of the Original
Agreement and the Addendum shall remain unchanged and in full force
and effect.

 

This
Second Addendum may be executed in two or more counterparts, each
of which shall be deemed an original but all of which together
shall constitute one and the same instrument.  Facsimile,
Portable Document Format (PDF) or photocopied signatures of the
Parties will have the same legal validity as original
signatures.

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Second
Addendum by their duly authorized representatives.

 

CHROMADEX,
INC.                                                                                      
THORNE RESEARCH, INC.

/s/ Troy
Rhonemus                                                                                             
/s/ Paul F. Jacobson

Name: Troy Rhonemus      
               
      
                                                       
Name: Paul F.
Jacobson                                       

Title: COO          
                 
          
             
    
                                             
Title: Chief Executive
Officer                              

Date: 9/14/2016        
               
              
                                                        
Date: September 14,
2016                                    

  

 

 

-4-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]